ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference

WESTON, Fla. — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will participate in a fireside chat at the 33rd Annual Oppenheimer Healthcare Conference to be held virtually March 13-15.

Details regarding ZyVersa’s fireside chat are as follows:

Event: 33rd Annual Oppenheimer Healthcare Conference
Date: Monday, March 13, 2023
Time: 11:20 AM EST
Location: Virtual –Link

“As a newly traded company on Nasdaq under the ticker “ZVSA,” we are pleased to discuss ZyVersa’s potential to build stockholder value as we advance development of our two platform technologies,” stated Mr. Glover. “ZyVersa is currently advancing two product candidates, Cholesterol Efflux MediatorTM VAR 200 in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, and inflammasome ASC inhibitor IC 100 which blocks initiation and perpetuation of damaging inflammation associated with numerous inflammatory diseases.”

To learn more about ZyVersa and its differentiated product Pipeline, please request a virtual one-on-one meeting with Mr. Glover through the conference portal.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. ZyVersa’s focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. The company’s development pipeline includes phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for treatment of rare kidney disease, focal segmental glomerulosclerosis (FSGS). Other potential indications for VAR 200 include Alport syndrome and diabetic kidney disease. ZyVersa’s development pipeline also includes novel inflammasome ASC inhibitor IC 100 to control damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has potential to treat numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.